Novel C5a agonist-based dendritic cell vaccine in a murine model of melanoma

Cell Cycle

Volumn 6, Issue 22, 2007, Pages 2835-2839

  Floreani, Anthony A ^a   Gunselman, Sandra J ^a   Heires, Arthur J ^a   Hauke, Ralph J ^a   Tarantolo, Stefano ^a   Jackson, John D ^b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

C5a agonist; Cell therapy; Dendritic cells; Melanoma; Tumor immunity

Indexed keywords

ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; COMPLEMENT COMPONENT C5A RECEPTOR AGONIST; DENDRITIC CELL VACCINE; DIMETHYL SULFOXIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; MONOPHENOL MONOOXYGENASE; PEPTIDE; SERYLVALYLTYROSYLASPARTYLPHENYLALANYLPHENYLALANYLVALYLTRYPTOPHYLLEUCINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CONTROLLED STUDY; COVALENT BOND; DENDRITIC CELL; FEMALE; MELANOMA; MOUSE; NONHUMAN; TUMOR GROWTH;

MURINAE; MUS;

EID: 37249071256     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.6.22.4899     Document Type: Article

References (19)

1. Mackensen A, Meidenbauer N, Vogl S, Laumer M, Berger J, Andreesen R. Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma. J Clin Oncol 2006; 24:5060-9.
2. Rosenberg SA, Zhai Y, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Seipp CA, Einhorn JH, Roberts B, White DE. Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens. J Natl Cancer Inst 1998; 90:1894-900.
3. Minev BR. Melanoma vaccines. Semin Oncol 2002; 29:479-93.
4. Slingluff Jr CL, Engelhard VH, Ferrone S. Peptide and dendritic cell vaccines. Clin Cancer Res 2006; 12:2342s-5s.
5. Taylor SM, Sherman SA, Kirnarsky L, Sanderson SD. Development of response-selective agonists of human C5a anaphylatoxin: Conformational, biological, and therapeutic considerations. Curr Med Chem 2001; 8:675-84.
6. Ulrich JT, Cieplak W, Paczkowski NJ, Taylor SM, Sanderson SD. Induction of an antigen-specific CTL response by a conformationally biased agonist of human C5a anaphylatoxin as a molecular adjuvant. The Journal of Immunology 2000; 164:5492-8.
7. Kirchhoff K, Weinmann O, Zwirner J, Begemann G, Gotze O, Kapp A, Werfel T. Detection of anaphylatoxin receptors on CD83+ dendritic cells derived from human skin. Immunology 2001; 103:210-7.
8. Lichtenfels R, Biddison WE, Schulz H, Vogt AB, Martin R. CARE-LASS (calcein-release-assay), an improved fluorescence-based test system to measure cytotoxic T lymphocyte activity. J Immunol Methods 1994; 172:227-39.
9. Neri S, Mariani E, Meneghetti A, Cattini L, Facchini A. Calcein-Acetyoxymethyl cytotoxicity assay: Standardization of a method allowing additional analyses on recovered effector cells and supernatants. Clin Diagn Lab Immunol 2001; 8:1131-5.
10. Ingram SB, O'Rourke MG. DC therapy for metastatic melanoma. Cytotherapy 2004; 6:148-53.
11. Morton DL. Immune response to postsurgical adjuvant active immunotherapy with Canvaxin polyvalent cancer vaccine: Correlations with clinical course of patients with metastatic melanoma. Dev Biol (Basel) 2004; 116:209-17, (discussion 29-36).
12. Kirkwood JM, Moschos S, Wang W. Strategies for the development of more effective adjuvant therapy of melanoma: Current and future explorations of antibodies, cytokines, vaccines, and combinations. Clin Cancer Res 2006; 12:2331s-6.
13. Niethammer AG, Xiang R, Becker JC, Wodrich H, Pertl U, Karsten G, Eliceiri BP, Reisfeld RA. A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. Nat Med 2002; 8:1369-75.
14. Jerome V, Graser A, Muller R, Kontermann RE, Konur A. Cytotoxic T lymphocytes responding to low dose TRP2 antigen are induced against B16 melanoma by liposome-encapsulated TRP2 peptide and CpG DNA adjuvant. J Immunother (1997) 2006; 29:294-305.
15. Palucka AK, Ueno H, Connolly J, Kerneis-Norvell F, Blanck JP, Johnston DA, Fay J, Banchereau J. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity. J Immunother (1997) 2006; 29:545-57.
16. Hao S, Bai O, Yuan J, Qureshi M, Xiang J. Dendritic cell-derived exosomes stimulate stronger CD8+ CTL responses and antitumor immunity than tumor cell-derived exosomes. Cell Mol Immunol 2006; 3:205-11.
17. Shimizu K, Thomas EK, Giedlin M, Mule JJ. Enhancement of tumor lysate- and peptide-pulsed dendritic cell-based vaccines by the addition of foreign helper protein. Cancer Res 2001; 61:2618-24.
18. Asada H, Kishida T, Hirai H, Shin-Ya M, Imanishi J, Takeuchi M, Mazda O. Combination vaccine of dendritic cells (DCs) and T cells effectively suppressed preestablished malignant melanoma in mice. Cancer Lett 2006; 240:83-93.
19. Mahnke K, Qian Y, Fondel S, Brueck J, Becker C, Enk AH. Targeting of antigens to activated dendritic cells in vivo cures metastatic melanoma in mice. Cancer Res 2005; 65:7007-12.